Skip to main content

EACR Molecular Pathology

Novosanis will be attending the EACR-OECI Joint Virtual Conference: Molecular Pathology Approach to Cancer on March 23 - 24. Our team is excited to meet and talk with you at our virtual booth with live chat functionality. To know more about our urine collection device Colli-Pee, and its applications in oncology, watch our on-demand satellite symposium.

Register here

Disclaimer

Novosanis is a wholly owned subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology. The Colli-Pee® family, the heart of the company, allows volumetric and standardized collection of first-void urine. The platform consists of variants capturing a range of urine volumes for different application purposes. Urine collection through the Colli-Pee® device is easy, comfortable, and more accurate than a regular urine cup. First-void urine has shown to improve detection of infectious diseases, including sexually transmitted infections as well as for some cancers applications. The Colli-Pee® device enables immediate mixing of the first-void urine sample with a preservative, improving stability of the urine specimen. Novosanis markets its products worldwide and has a global customer base.